The myocardial phenotype of Fabry disease pre-hypertrophy and pre-detectable storage

53Citations
Citations of this article
51Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Aims: Cardiac involvement in Fabry disease (FD) occurs prior to left ventricular hypertrophy (LVH) and is characterized by low myocardial native T1 with sphingolipid storage reflected by cardiovascular magnetic resonance (CMR) and electrocardiogram (ECG) changes. We hypothesize that a pre-storage myocardial phenotype might occur even earlier, prior to T1 lowering. Methods and results: FD patients and age-, sex-, and heart rate-matched healthy controls underwent same-day ECG with advanced analysis and multiparametric CMR [cines, global longitudinal strain (GLS), T1 and T2 mapping, stress perfusion (myocardial blood flow, MBF), and late gadolinium enhancement (LGE)]. One hundred and fourteen Fabry patients (46 ± 13 years, 61% female) and 76 controls (49 ± 15 years, 50% female) were included. In pre-LVH FD (n = 72, 63%), a low T1 (n = 32/72, 44%) was associated with a constellation of ECG and functional abnormalities compared to normal T1 FD patients and controls. However, pre-LVH FD with normal T1 (n = 40/72, 56%) also had abnormalities compared to controls: reduced GLS (-18 ± 2 vs. -20 ± 2%, P < 0.001), microvascular changes (lower MBF 2.5 ± 0.7 vs. 3.0 ± 0.8 mL/g/min, P = 0.028), subtle T2 elevation (50 ± 4 vs. 48 ± 2 ms, P = 0.027), and limited LGE (%LGE 0.3 ± 1.1 vs. 0%, P = 0.004). ECG abnormalities included shorter P-wave duration (88 ± 12 vs. 94 ± 15 ms, P = 0.010) and T-wave peak time (Tonset - Tpeak; 104 ± 28 vs. 115 ± 20 ms, P = 0.015), resulting in a more symmetric T wave with lower T-wave time ratio (Tonset - Tpeak)/(Tpeak - Tend) (1.5 ± 0.4 vs. 1.8 ± 0.4, P < 0.001) compared to controls. Conclusion: FD has a measurable myocardial phenotype pre-LVH and pre-detectable myocyte storage with microvascular dysfunction, subtly impaired GLS and altered atrial depolarization and ventricular repolarization intervals.

References Powered by Scopus

Safety and efficacy of recombinant human α-galactosidase a replacement therapy in Fabry's disease

1485Citations
N/AReaders
Get full text

Normalized left ventricular systolic and diastolic function by steady state free precession cardiovascular magnetic resonance.

687Citations
N/AReaders
Get full text

Long-term effects of enzyme replacement therapy on fabry cardiomyopathy. Evidence for a better outcome with early treatment

429Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Coronary Microvascular Dysfunction Across the Spectrum of Cardiovascular Diseases: JACC State-of-the-Art Review

339Citations
N/AReaders
Get full text

Pathophysiology of Coronary Microvascular Dysfunction

70Citations
N/AReaders
Get full text

Diagnosis and Management of Rare Cardiomyopathies in Adult and Paediatric Patients. A Position Paper of the Italian Society of Cardiology (SIC) and Italian Society of Paediatric Cardiology (SICP)

45Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Augusto, J. B., Johner, N., Shah, D., Nordin, S., Knott, K. D., Rosmini, S., … Namdar, M. (2021). The myocardial phenotype of Fabry disease pre-hypertrophy and pre-detectable storage. European Heart Journal Cardiovascular Imaging, 22(7), 790–799. https://doi.org/10.1093/ehjci/jeaa101

Readers over time

‘20‘21‘22‘23‘24‘2506121824

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 16

70%

Researcher 5

22%

Professor / Associate Prof. 2

9%

Readers' Discipline

Tooltip

Medicine and Dentistry 20

80%

Neuroscience 2

8%

Psychology 2

8%

Nursing and Health Professions 1

4%

Save time finding and organizing research with Mendeley

Sign up for free
0